AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
Acquiring Company
Pulmatrix
Acquired Company
Eos SENOLYTIX
LexingtonHoustonHealthcareBiotechnologyHealth CareDescription
On September 25, 2026, Pulmatrix, Inc. submitted a definitive proxy for its planned merger with Eos SENOLYTIX, Inc. The merger aims to consolidate resources and expertise, with significant share issuance anticipated. Following the merger, Eos securityholders are expected to own approximately 94% of the combined entity. This merger is set to enhance Pulmatrix's position in the biotechnology sector.
Fundz sees it the moment Pulmatrix makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Eos SENOLYTIX?
Eos SENOLYTIX was acquired by Pulmatrix, based in Lexington. The deal was reported on September 26, 2026. Pulmatrix is publicly traded (PULM) and operates in Healthcare.
When did Pulmatrix acquire Eos SENOLYTIX?
Pulmatrix's acquisition of Eos SENOLYTIX was reported on September 26, 2026. On September 25, 2026, Pulmatrix, Inc. submitted a definitive proxy for its planned merger with Eos SENOLYTIX, Inc. The merger aims to consolidate resources and expertise, with significant share issuance anticipated. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Eos SENOLYTIX do?
Eos SENOLYTIX, Inc. is a biotechnology company specializing in the development of novel gerotherapeutic peptides aimed at targeting mitochondrial dysfunction in aging-related diseases. It is privately held, operating in Biotechnology, and is based in Houston.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.